Indianapolis-based Eli Lilly and Co. announced Wednesday it intends to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company developing oral therapies for inflammatory-mediated diseases.
The Indianapolis-based company received U.S. regulatory approval last week for its second medicine in 18 months in what it describes as the $1.3 billion dog dermatology market.
Attorney General Todd Rokita said the lawsuit, filed last Wednesday in the Lake County Superior Court, is part of his office’s intensifying efforts to lower insulin prices and improve health care affordability.
Participants in the program via the Indiana Life Sciences Association can receive significant discounts—up to 75%—off list prices on goods including lab equipment, office supplies, corporate travel and insurance.
As of Nov. 13, Eli Lilly and Co.’s market capitalization was $967 billion and flirting with a rare $1 trillion. Its stock price in November surpassed $1,000 per share, up more than 25% for the year.
Novo Nordisk’s Wegovy pills are expected to be available within weeks, while Indianapolis-based Eli Lilly and Co. waits for approval for its daily GLP-1 pill, orforglipron.
Eli Lilly and Co.’s career website this month listed 254 job openings in Indianapolis and another 90 in Lebanon, accounting for more than three-quarters of the 445 open positions the pharmaceutical giant listed across the United States.
According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival’s GLP-1 injectable, the Indianapolis-based drugmaker said.
For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that limits choice.
An Elanco spokeswoman said cuts to the company’s Indiana workforce are “very minimal.” Most of the eliminated positions are from the company’s planned closure of its German R&D facility.
Lilly’s planned Huntsville site is part of the drugmaker’s commitment to add four U.S. manufacturing sites through a $27 billion reshoring investment unveiled early this year.
The decision is the latest in a series of moves to make its GLP-1 blockbuster more widely available and affordable.
The Indianapolis-based drugmaker said the coverage would be administered by third-party administrators to provide employers “transparent, flexible cost-sharing options” for their workers.
Yet promising health tech companies still leave the state to raise growth capital.
Indianapolis-based Roche Diagnostics said while the survey was conducted in Europe, its implications are global and reflect challenges in the United States.
Dr. Michael Meneghini waited out a two-year noncompete clause after leaving Indiana University Health before opening the $35 million Indiana Orthopedic Institute early this year.
Indianapolis-based Alloy Partners says its OneHealth Studio, a venture studio that quietly began operating last month in partnership with Elanco Animal Health Inc., will be ready to create its first startups early next year.
Despite reporting a loss, the company saw quarterly growth in the double digits and raised its full-year earnings estimate.
Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on weight loss drugs, including Lilly medications.
Purdue University’s new Center for Musculoskeletal Engineering in Indianapolis has a growth plan that metaphorically matches a healthy growing body.
